Clover Biopharmaceuticals Co., Ltd. will hold its Annual General Meeting on June 20, 2024. The venue will be located in Chengdu High New Zone, China (Sichuan) Pilot Free Trade Zone. The General Meeting will consider a number of ordinary resolutions, including the adoption of the audited consolidated financial statements and related reports for the year ended December 31, 2023, the re-election of Dr. Leung Pan, Dr. Wu Xiaobin and Mr. Jeffrey FARROW as directors, and authorizing the Board to determine the remuneration of directors. In addition, EY will be reappointed as auditor and authorized by the Board of Directors to determine their remuneration. The General Meeting will also consider authorizing directors to issue new shares or share options within a specified period and...Show More

Clover Biopharmaceuticals Co., Ltd. will hold its Annual General Meeting on June 20, 2024. The venue will be located in Chengdu High New Zone, China (Sichuan) Pilot Free Trade Zone. The General Meeting will consider a number of ordinary resolutions, including the adoption of the audited consolidated financial statements and related reports for the year ended December 31, 2023, the re-election of Dr. Leung Pan, Dr. Wu Xiaobin and Mr. Jeffrey FARROW as directors, and authorizing the Board to determine the remuneration of directors. In addition, EY will be reappointed as auditor and authorized by the Board of Directors to determine their remuneration. The General Meeting will also consider authorizing directors to issue new shares or share options within a specified period and to repurchase company shares not exceeding 10% of the total issued share capital. The special resolution included the approval of amendments to the Company's Articles of Association and the Articles of Association. Shareholders will not be able to register shares from 14 to 20 June 2024 in order to be eligible to attend the General Meeting.